Meeting slides
Interactive presentation

Is It Systemic Mastocytosis? Best Practices for Diagnosis and Management

Listen to Barbara share her story about being diagnosed and living with indolent SM.
Suggested Readings

American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting.

San Antonio, Texas. February 24-27, 2023.

Results from Pioneer: a randomized, double-blind, placebo-controlled, phase 2 study of avapritinib in patients with indolent systemic mastocytosis.

Akin C, Elberink HO, Gotlib J, et al. American Society of Hematology Virtual Conference; December 5-8, 2020. Abstract 1248.

Patients with mast cell activation symptoms and elevated baseline serum tryptase level have unique bone marrow morphology.

Giannetti MP, Akin C, Hufdhi R, et al. J Allergy Clin Immunol. 2021;147(4):1497-1501.e1.

Patient perceptions in mast cell disorders.

Jennings SV, Slee VM, Zack RM, et al. Immunol Allergy Clin North Am. 2018;38(3):505-525.

Patient-reported outcomes among patients with systemic mastocytosis in routine clinical practice: Results of the TouchStone SM Patient Survey.

Mesa RA, et al. Cancer. 2022; 128(20): 3691-3699.

Systemic mastocytosis: molecular landscape and implications for treatment.

Monaldi C, De Santis S, Mancini M, et al. Mediterr J Hematol Infect Dis. 2021;13(1):e2021046.

Systemic mastocytosis in adults: 2021 update on diagnosis, risk stratification and management.

Pardanani A. Am J Hematol. 2021;96(4):508-525. 

Mast cells, mastocytosis, and related disorders.

Theoharides TC, Valent P, Akin C. N Engl J Med. 2015;373(2):163-172.

Personalized management strategies in mast cell disorders: ECNM-AIM user's guide for daily clinical practice.

Valent P, Hartmann K, Schwaab J, et al. J Allergy Clin Immunol. 2022;10(8):1999-2012.e1996.

Midostaurin in patients with indolent systemic mastocytosis: an open-label phase 2 trial.

van Anrooij B, Oude Elberink JNG, Span LFR, et al. J Allergy Clin Immunol2018;142(3):1006-1008. e7.

Systemic mastocytosis: multidisciplinary approach.

Zanotti R, Tanasi I, Crosera L, et al. Mediterr J Hematol Infect Dis. 2021;13(1):e2021068.

Linked Resources

Clinical Guidelines

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Arber DA, Orazi A, Hasserjian R, et al. Blood. 2016;127(20):2391-2405.

The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms.

Khoury JD, Solary E, Abla O, et al. Leukemia. 2022;36(7):1703-1719.

NCCN Clinical Practice Guidelines in Oncology: Systemic Mastocytosis.

National Comprehensive Cancer Network.

Patient Resources

The Mast Cell Disease Society, Inc. (TMS)

TMS is dedicated to providing multifaceted support to patients, families, and medical professionals in the community and to leading the advancement of knowledge and research in mast cell diseases through education, advocacy, and collaboration.

The European Competence Network on Mastocytosis (ECNM)

The goal of the ECNM is to improve disease-recognition, diagnosis, and therapy in patients with mastocytosis in Europe.

National Organization for Rare Disorders (NORD)

NORD is a patient advocacy organization committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research, and patient services. 

Related activities
0.00 CE

Making the Rounds on Systemic Mastocytosis

Accelerating Diagnosis and Treatment

Faculty: Mariana C. Castells, MD; Tracy I. George, MD; Patricia L. Lugar,MD; Anne L. Maitland, MD;
Release: 02/25/2023
Expiration: 03/10/2023
1.50 CME/CE

Making the Rounds on Systemic Mastocytosis

Accelerating Diagnosis and Treatment